Clinical trial
A Phase 2, Randomized, Double Blind, Placebo Controlled, Dose Range Finding Study to Access the Efficacy and Safety of Intramuscular Injection of Human Placenta- Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy.
NCT02552277 is registered in ClinicalTrials.gov with Celularity Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double Blind, Placebo Controlled, Dose Range Finding Study to Access the Efficacy and Safety of Intramuscular Injection of Human Placenta- Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy.
- Lead sponsor
- Celularity Incorporated
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 27, 2015
- Completion date
- October 30, 2017
- Enrollment
- 26 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.